TGF-beta and cancer
PRINCIPAL INVESTIGATORS
- Javier Vaquero Rodríguez
CLINICAL RESEARCHERS
- Mariona Calvo Campos
- Emilio Ramos Rubio
- Teresa Serrano Piñol
POSTDOCTORAL RESEARCHERS
- Josep Amengual Segura
- Paula Segales Rovira
PREDOCTORAL RESEARCHERS
- Ana Cantos Cortes
- Gemma Gonfaus Ortiz
- Rosanna Scialpi
SCIENTIFIC SUPPORT
- Esther Bertran Rodriguez
Cancer
Oncobell
Scientific production
14
PAPERS
Average IF: 8,44
4
LED PAPERS
Average IF: 16,93
3 PUBLICATIONS IN FIRST DECILE
10 PUBLICATIONS IN FIRST QUARTILE
12 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Amengual,J;Gonzalez Sanchez,E;Yanez Bartolome,M;Sererols Vinas,L;Ravichandra,A;Guiton,C;Fuste,NP et al, NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts, Signal Transduct Target Ther, 2025;10(1):257-257, doi:10.1038/s41392-025-02347-z
- Cantos Cortes,A;Amengual,J;Espinosa Sotelo,R;Bertran,E;Vaquero,J;de Galarreta,MR;Molina Sanchez,P et al, New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor-Beta in Liver Tumorigenesis, Liver Int, 2025;45(10):doi:10.1111/liv.70351
- Scialpi,R;Espinosa Sotelo,R;Bertran,E;Dituri,F;Giannelli,G;Fabregat,I, New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-ß Therapies Based on Tumor Characteristics, Int. J. Mol. Sci., 2025;26(6):doi:10.3390/ijms26062430
- Vinyals,A;Ferreres,JR;Campos Martin,R;Torres,OJC;Mainez,J;Puig Butille,JA;Marcoval,J et al, Regulatory Mechanisms of SPARC Overexpression in Melanoma Progression, Int. J. Mol. Sci., 2025;26(17):doi:10.3390/ijms26178743
- Llorens Giralt,P;Ruiz Romero,M;Nurtdinov,R;Herranz Itúrbide,M;Vicent,GP;Serras,F;Fabregat,I et al, Sequential activation of transcription factors promotes liver regeneration through specific and developmental enhancers., Cell Genom, 2025;5(7):100887-100887, doi:10.1016/j.xgen.2025.100887
Research highlights
PROJECTS
5 Ongoing competitive projects
5 Started clinical trials
10 Ongoing clinical trials
1 Ongoing non competitive project
INNOVATION
1 license
NETWORKS
CIBEREHD
COST action Precision BTC Network
AGAUR SGR GRC 2021
Selected projects
- PID2021-122551OB-I00. Descifrando el papel de la NADPH oxidasa NOX4 en el carcinoma hepatocelular: relevancia en células tumorales y estroma y relación con la vía del TGF-beta. Ministerio de Ciencia e Innovación. Budget: 344.850€. 2022-2026. PI: MARIA ISABEL FABREGAT ROMERO.
- PRYGN211279FABR. Towards a precision medicine using TGF-β inhibitors in hepatocellular carcinoma and cholangiocarcinoma. Asociación Española Contra el Cáncer (AECC). Budget: 299.813,75€. 2021-2025. PI: MARIA ISABEL FABREGAT ROMERO.
- 2021 SGR 00029. Paper del TGF-beta i de l’estrès oxidatiu en patologies humanes [Role of TGF-beta and the oxidative stress in human pathologies]. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 40.000€. 2022-2025. PI: MARIA ISABEL FABREGAT ROMERO.
- PRE2022-101761. AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE DOCTORES 2022. Ministerio de Ciencia e Innovación. Budget: 111.758€. 2023-2027. PI: MARIA ISABEL FABREGAT ROMERO.
- CO44668. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA. F-Hoffmann-La Roche Ltd. Budget: 151.872€. 2023- . PI: MARIONA CALVO CAMPOS.